TrialSignal transduction and targeted therapy2024

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.

Jia Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.